Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Momenta chronicles

Momenta chronicles

Momenta (MNTA) dropped 58% last week after the company and partner Sandoz received a not approvable letter from FDA for an ANDA for M-Enoxaparin. The stock has dropped more than 80% since its peak

Read the full 355 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE